Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents.
1979451 citationsEliezer Huberman, Michael F. CallahamProceedings of the National Academy of Sciencesprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Michael F. Callaham
Since
Specialization
Citations
This map shows the geographic impact of Michael F. Callaham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael F. Callaham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael F. Callaham more than expected).
Fields of papers citing papers by Michael F. Callaham
This network shows the impact of papers produced by Michael F. Callaham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael F. Callaham. The network helps show where Michael F. Callaham may publish in the future.
Co-authorship network of co-authors of Michael F. Callaham
This figure shows the co-authorship network connecting the top 25 collaborators of Michael F. Callaham.
A scholar is included among the top collaborators of Michael F. Callaham based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Michael F. Callaham. Michael F. Callaham is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Fisher, Paul B., David Schachter, Richard E. Abbott, Michael F. Callaham, & Eliezer Huberman. (1984). Membrane lipid dynamics in human promyelocytic leukemia cells sensitive and resistant to 12-O-tetradecanoylphorbol-13-acetate induction of differentiation.. PubMed. 44(12 Pt 1). 5550–4.30 indexed citations
6.
Au, William W., Michael F. Callaham, M. Linda Workman, & E Huberman. (1983). Double minute chromatin bodies and other chromosome alterations in human myeloid HL-60 leukemia cells susceptible or resistant to induction of differentiation by phorbol-12-myristate-13-acetate.. PubMed. 43(12 Pt 1). 5873–8.13 indexed citations
7.
Murao, Shinichi, M. A. Gemmell, Michael F. Callaham, N L Anderson, & Eliezer Huberman. (1983). Control of macrophage cell differentiation in human promyelocytic HL-60 leukemia cells by 1,25-dihydroxyvitamin D3 and phorbol-12-myristate-13-acetate.. PubMed. 43(10). 4989–96.131 indexed citations
8.
Huberman, Eliezer, et al.. (1982). Cell differentiation, alterations in polyamine levels, and specific binding of phorbol diesters in cultured human cells.. PubMed. 7. 405–16.1 indexed citations
Cabot, Myles C., Clement J. Welsh, Michael F. Callaham, & Eliezer Huberman. (1980). Alterations in lipid metabolism induced by 12-O-tetradecanoylphorbol-13-acetate in differentiating human myeloid leukemia cells.. PubMed. 40(10). 3674–9.45 indexed citations
Huberman, Eliezer & Michael F. Callaham. (1979). Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents.. Proceedings of the National Academy of Sciences. 76(3). 1293–1297.451 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.